全球合同研究组织 (CRO) 市场:增长机会

随着许多临床研究在印度、印度尼西亚、中国、拉丁美洲、中东和南非等新兴国家和第三世界国家/地区进行，该行业的动态正在发生显着变化。 因此，一些本地 CRO 正在通过与更大的全球 CRO 合作以支持本地临床研究来扩大其市场范围。

此外，该行业越来越多地采用大规模分散式临床试验，在 2020-21 年和 2021-2022 年分别实现了 50% 和 28% 的同比增长。 这些变化增加了电子临床解决方案供应商的进入，促进了与 CRO 和製药公司的合作，以提供数据采集、药物警戒和研究管理等前沿解决方案。

本报告考察了全球合同研究组织 (CRO) 市场，并提供了市场概况、影响市场增长的各种因素的分析、提供的服务和利益相关者、投资趋势、收入预测、各个细分市场，我们编制了详细分析区域、竞争分析、增长机会分析等。

内容

战略要务

• 增长问题
• 战略要务 8 (TM)
• 三大战略要务的影响
• 增长机会推动增长PipelineEngine (TM)

增长机会分析

• 分析范围
• 分类
• 外围部门
• 市场趋势分析
• 供应商生态系统
• 增长动力
• 抑制增长的因素

服务和利益相关者

• 服务和利益相关者
• CRDMO:外包的未来
• 支持药物发现和开发的 CRDMO 交易

临床研究的数字化和去中心化

• 药物开发价值链的数字化
• 临床研究数字化
• DCT:对 CRO 行业的未来影响

投资趋势

• 投资趋势:药物开发的协作方法
• 早期到晚期 CRO 服务协作:非临床
• 早期至晚期 CRO 服务合作:临床
• 支持产业整合的技术合作伙伴关係
• 通过行业收购扩大 CRO 的专业知识

增长机会分析:CRO

• 增长指标
• 预测假设
• 收入预测
• 利润预测:临床/非临床
• 收入预测分析

增长机会分析:非临床 CRO

• 增长指标
• 盈利预测的假设和研究方法
• 主要服务:药物发现和临床前研究
• 药物发现和临床前开发的细微差别
• 医药研发费用
• 收入预测
• 收入预测:按非临床开发阶段
• 收入预测分析

增长机会分析:临床

• 增长指标
• 收入预测假设
• 收入预测:研究方法
• 收入预测
• 收入预测:按临床开发阶段
• 利润率预测:按临床开发阶段
• 收入预测分析
• 临床研究:按治疗领域分类

区域分析

• 按地区划分的收入份额分析
• 北美:主要趋势
• 北美:按临床开发阶段预测收入
• 北美:收入预测分析
• 欧洲:主要趋势
• 欧洲:按临床开发阶段预测收入
• 欧洲:收入份额分析
• 亚太地区:主要趋势
• 亚太地区:按临床开发阶段预测收入
• 亚太地区:收入份额分析
• 其他地区:主要趋势
• 其他地区:按临床开发阶段预测收入
• 其他地区:收入份额分析

竞争评级

• 竞争环境
• 主要公司
• 收益分成
• 收益分成分析

临床试验费用及周边服务评估

• 按服务类型细分的费用
• 外围服务:分析测试服务
• 外围服务:临床结果和上市后监测
• 外围服务:数据采集和管理

增长机会领域

• 增长机会 1:药物发现和临床前药物测试的灵活合作模式
• 增长机会 2:生物製品定制测试解决方案的生物分析 CRO 合作伙伴关係
• 增长机会 3:药物警戒服务的电子临床解决方案
• 增长机会 4:AI 驱动的肿瘤学临床试验设计、招募和执行

下一步

Strong Competitive Intensity is Mandating a Greater Industry Convergence Resulting in a Strong Market Growth

The COVID-19 pandemic led to a sudden surge in R&D activities across the world. Both small and large pharmaceutical and biotech companies were engaged in tremendous efforts to either develop new molecules or repurpose existing therapies as potential drugs for COVID-19 treatment.

The trend is likely to continue with small-to-medium-segment and emerging biopharma participants introducing novel therapies across various indications, primarily oncology, infectious diseases, and neurology. Per Pharma Intelligence's annual R&D review, global non-clinical and clinical pipelines have grown by leaps and bounds--more than 10,000 molecules were in preclinical development and about 6,000 molecules were in clinical development as of January 2022.

Industry dynamics saw a huge shift with much of the clinical research being conducted in emerging economies and third-world countries, such as India, Indonesia, China, LATAM, the Middle East, and South Africa. As a result, several local CROs expanded their market reach by partnering with larger, global CROs and providing local clinical research support. The industry also moved to adopt large-scale decentralized clinical trials, with a year-over-year growth of 50% and 28% between 2020-2021 and 2021-2022, respectively. Such changes expanded the participation of eClinical solution vendors and encouraged collaborations with CROs and pharmaceutical companies, providing cutting-edge solutions for data capture, pharmacovigilance, trial management, and other applications.

Drug discovery and preclinical service outsourcing (traditionally conducted in house because of IP infringement issues) has increased, owing to the rise in specialized drug discovery and preclinical CROs and the CRDMO model gaining traction. CROs work as risk-sharing partners and offer one-stop-shop services to pharmaceutical companies, thereby cutting down costs and shortening the timeline of development.

Key Issues Addressed:

• What are the general industry trends pertaining to the global CRO industry?

• What are the key drivers triggering large-scale outsourcing of both early- and late-stage nonclinical and clinical development?

• What are the key emerging business models providing a competitive advantage to pharmaceutical sponsors and how is it supporting industry convergence?

• Who are the leading participants driving market growth?

• What is the opportunity for small- to medium-segment CRO participants in a sea of competitors?

• How is the application of technology supporting the growth of the CRO market and, in general, the drug development outsourcing services?

Table of Contents

Strategic Imperatives

• Why is it Increasingly Difficult to Grow?
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on the Contract Research Organization (CRO) Industry
• Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis

• Scope of Analysis
• Segmentation
• Peripheral Segments
• Market Trend Analysis
• Market Trend Analysis (continued)
• Vendor Ecosystem
• Growth Drivers
• Growth Restraints

Services and Stakeholders

• Services and Stakeholders
• CRDMO-The Future of Outsourcing
• CRDMO-The Future of Outsourcing (continued)
• CRDMO Transactions to Support Drug Discovery and Development
• CRDMO Transactions to Support Drug Discovery and Development (continued)

Digitization and Decentralization of Clinical Research

• Digitization of the Drug Development Value Chain
• Digitization of Clinical Research
• DCTs-Future Impact on the CRO Industry

Investment Trends

• Investment Trends-Collaborative Approach for Drug Development
• Early- to Late-stage CRO Service Collaboration-Nonclinical
• Early- to Late-stage CRO Service Collaboration-Nonclinical (continued)
• Early- to Late-stage CRO Service Collaboration-Nonclinical (continued)
• Early- to Late-stage CRO Service Collaboration-Clinical
• Early- to Late-stage CRO Service Collaboration-Clinical (continued)
• Early- to Late-stage CRO Service Collaboration-Clinical (continued)
• Technology Partnerships Supporting Industry Convergence
• Technology Partnerships Supporting Industry Convergence (continued)
• Technology Partnerships Supporting Industry Convergence (continued)
• Expanding CRO Expertise through Industry Acquisitions
• Expanding CRO Expertise through Industry Acquisitions (continued)
• Expanding CRO Expertise through Industry Acquisitions (continued)
• Expanding CRO Expertise through Industry Acquisitions (continued)
• Expanding CRO Expertise through Industry Acquisitions (continued)
• Expanding CRO Expertise through Industry Acquisitions (continued)

Growth Opportunity Analysis-CRO

• Growth Metrics
• Forecast Assumptions
• Forecast Assumptions (continued)
• Revenue Forecast
• Revenue Forecast-Clinical vs. Nonclinical
• Revenue Forecast Analysis
• Revenue Forecast Analysis (continued)

Growth Opportunity Analysis-Nonclinical CRO

• Growth Metrics
• Revenue Forecast Assumptions and Methodology
• Key Services-Drug Discovery and Preclinical Research,
• Nuances of Drug Discovery and Preclinical Development
• Pharmaceutical R&D Expenditure
• Revenue Forecast
• Revenue Forecast by Nonclinical Phases of Development
• Revenue Forecast Analysis
• Revenue Forecast Analysis (continued)
• Revenue Forecast Analysis (continued)

Growth Opportunity Analysis-Clinical

• Growth Metrics
• Revenue Forecast Assumptions
• Revenue Forecast Methodology
• Revenue Forecast
• Revenue Forecast by Clinical Phases of Development
• Percent Revenue Forecast by Clinical Phases of Development
• Revenue Forecast Analysis
• Revenue Forecast Analysis (continued)
• Clinical Trial Split by Therapy Area

Regional Analysis

• Revenue Share Analysis By Region
• North America-Key Trends
• North America-Revenue Forecast by Clinical Development Phase
• North America-Revenue Forecast Analysis
• Europe-Key Trends
• Europe-Revenue Forecast by Clinical Development Phase
• Europe-Revenue Share Analysis
• APAC-Key Trends
• APAC-Revenue Forecast by Clinical Development Phases
• APAC-Revenue Share Analysis
• RoW-Key Trends
• RoW-Revenue Forecast by Clinical Development Phase
• RoW-Revenue Share Analysis

Competitor Assessment

• Competitive Environment
• Key Competitors
• Revenue Share
• Revenue Share Analysis
• Revenue Share Analysis (continued)

Clinical Trial Costs and Peripheral Services Assessment

• Cost Split by Service Type
• Peripheral Services-Analytical Testing Services
• Peripheral Services-Clinical Outcomes and Post-market Surveillance
• Peripheral Services-Data Capture and Management

Growth Opportunity Universe

• Growth Opportunity 1: Agile Partnership Models for Drug Discovery and Preclinical Drug Testing
• Growth Opportunity 1: Agile Partnership Models for Drug Discovery and Preclinical Drug Testing (continued)
• Growth Opportunity 2: Bioanalytical CRO Partnerships for Customized Testing Solutions for Biologics
• Growth Opportunity 2: Bioanalytical CRO Partnerships for Customized Testing Solutions for Biologics (continued)
• Growth Opportunity 3: eClinical Solutions for Pharmacovigilance Services
• Growth Opportunity 3: eClinical Solutions for Pharmacovigilance Services (continued)
• Growth Opportunity 4: AI-enabled Oncology Trial Design, Recruitment, and Execution
• Growth Opportunity 4: AI-enabled Oncology Trial Design, Recruitment, and Execution (continued)

Next Steps

• Your Next Steps
• Why Frost, Why Now?
• List of Exhibits
• List of Exhibits (continued)
• Legal Disclaimer